Improved Drug Susceptibility Testing (DST) for Mycobacteria
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Allergy and Infectious Diseases is soliciting research to develop advanced drug susceptibility tests for mycobacterial pathogens, including those causing tuberculosis and clinically significant non-tuberculous mycobacterial infections. With rising global and domestic rates of drug-resistant TB and an increasing incidence of NTM lung disease—particularly among women and older adults—current culture-based testing methods are no longer sufficient due to their slow turnaround times. The initiative aims to fund innovative approaches that enable rapid detection of drug susceptibility without relying on full culture growth, incorporating both genotypic and improved phenotypic technologies. These next-generation assays are critical for guiding timely, effective treatment, curbing the spread of resistant strains, and reducing transmission. The program is authorized under Sections 301 and 405 of the Public Health Service Act and governed by federal regulations under 42 CFR Part 52 and 2 CFR Part 200, with inquiries and submissions directed to the Division of Microbiology and Infectious Diseases at niaiddst@mail.nih.gov.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
